Cristofanilli Jefferson SABCS '13

Noted oncologist Massimo Cristofanilli, M.D. discusses research he co-authored that compared molecular subtyping of breast cancer (with Agendia’s MammaPrint and BluePrint) to traditional clinical pathology methods. Molecular subtyping is used to better match patients to the most effective therapy. The study of more than 300 patients found that molecular subtyping with MammaPrint and BluePrint was substantially more accurate in identifying the underlying biology of each patient’s form of cancer. The greater accuracy of these tests has “tremendous implications” for targeting treatments to each patient’s type of tumor, says Dr. Cristofanilli.

• Category

  • Science & Technology

• License

  • Standard YouTube License